IBM reported on 3/11/2019 that it used machine learning to identify sets of proteins in blood that are predictive of a biomarker in spinal fluid. This new type of blood testing is not only an effective and noninvasive diagnostic technology for early-onset Alzheimer's, but also the first to use a machine learning approach. Patent data further indicate IBM's commitment to using artificial intelligence in the biotech sector.
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
View Patent Forecast®
Top Corporations
News and Insights
Data Visualization
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
